Pathological and radiological response following neoadjuvant treatments in primary localized resectable myxofibrosarcoma and undifferentiated pleomorphic sarcoma of the extremities and trunk wall

🔗 Access full article via ACS Cancer

Clinical data including residual visible tumor (VT%) on surgical specimen and Response Evaluation Criteria in Solid Tumor (RECIST) were retrieved . Of 693 patients affected by primary MFS and UPS, 233 were treated by neoadjuvant chemotherapy (naChT) or radiotherapy . VT% was ≤5% in 13/46 (28.2%), 24/99, and 40/88 (45.4%) patients, respectively .